



First treatments with CoreTherm® Eagle to be performed next week – Key milestone for ProstaLund

ProstaLund announced today that the first clinical treatments using the new CoreTherm® Eagle treatment platform will take place in Sweden next week. This marks an important milestone in the company's development and a crucial step in providing healthcare providers and patients with a more modern and user-friendly solution.

In November 2024, the company announced that the first ten CoreTherm® Eagle units had been produced and that the launch was imminent. During the final release testing, a need for a few minor software adjustments was identified, which caused a slight delay in the timeline. The system has now been fully tested and is ready for clinical use.

"We are very pleased to now begin the first treatments with CoreTherm® Eagle. This is a significant milestone for us and a clear result of the focused internal efforts. I want to extend a big thank you to all our employees for their fantastic work. Reaching this point gives us new energy to further strengthen our presence with customers and continue delivering value to both patients and healthcare providers," says Anders Kristensson, CEO of ProstaLund.

CoreTherm® Eagle builds on the proven and well-established technology that has been developed and refined over 25 years in earlier CoreTherm® platforms, used in over 30,000 treatments for benign prostatic hyperplasia in the Nordics. The new CoreTherm® Eagle has undergone significant technical and component upgrades. Among other things, the calculation of recommended treatment goals has been automated and integrated into the new platform. This provides increased support for the user and further enhances ease of use.

"The next step in the launch is Denmark, our second-largest market, followed by continued international expansion. With CoreTherm® Eagle, new opportunities are opening up to offer more clinics—both in the Nordics and globally—an effective treatment method. Together, we can improve the quality of life for men with prostate problems," says Anders Kristensson, CEO of ProstaLund.

For further information, please contact:

Anders Kristensson, CEO
Tel. +46 (0) 769 42 12 16
Email: anders.kristensson@prostalund.com

PRESS RELEASE
14 May 2025 10:45:00 CEST



About CoreTherm®

CoreTherm® is a minimally invasive transurethral microwave thermotherapy for benign prostatic enlargement (BPH). The treatment is performed in an outpatient setting under local anaesthesia and takes less than 15 minutes. No general anaesthesia or spinal block is needed. Follow-up data five years after CoreTherm® treatment shows clinical outcomes comparable to those seen after surgery/TURP (transurethral resection of the prostate), but with lower risk of serious complications. For more information visit, www.coretherm.com.

About ProstaLund

ProstaLund AB (publ) is a Swedish medtech company headquartered in Lund that develops and markets innovative products for the treatment of Benign Prostatic Enlargement (BPH). The company has patented the CoreTherm® Concept, a customised thermal treatment for BPE. ProstaLund is listed on Nasdaq First North Growth Market and has approximately 3,500 shareholders. For more information, visit www.prostalund.se. Our press releases are also available to read and download here: www.prostalund.se/pressmeddelanden

Certified Adviser:

Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se

Attachments

First treatments with CoreTherm® Eagle to be performed next week – Key milestone for ProstaLund